CU20190056A7 - Ácidos carboxílicos de benzimidazoles y 4-aza, 5-aza, 7-aza y 4,7-diaza-benzimidazoles como agonistas receptores de glp-1, útiles para tratar o prevenir enfermedades cardiometabólicas - Google Patents

Ácidos carboxílicos de benzimidazoles y 4-aza, 5-aza, 7-aza y 4,7-diaza-benzimidazoles como agonistas receptores de glp-1, útiles para tratar o prevenir enfermedades cardiometabólicas

Info

Publication number
CU20190056A7
CU20190056A7 CU2019000056A CU20190056A CU20190056A7 CU 20190056 A7 CU20190056 A7 CU 20190056A7 CU 2019000056 A CU2019000056 A CU 2019000056A CU 20190056 A CU20190056 A CU 20190056A CU 20190056 A7 CU20190056 A7 CU 20190056A7
Authority
CU
Cuba
Prior art keywords
aza
benzimidazoles
diaza
glp
useful
Prior art date
Application number
CU2019000056A
Other languages
English (en)
Other versions
CU24573B1 (es
Inventor
Gary Erik Aspnes
Scott W Bagley
John M Curto
Matthew S Dowling
David James Edmonds
Mark E Flanagan
Kentaro Futatsugi
David A Griffith
Kim Huard
Gajendra Ingle
Wenhua Jiao
Chris Limberakis
Alan M Mathiowetz
David W Piotrowski
Roger B Ruggeri
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60702906&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CU20190056(A7) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of CU20190056A7 publication Critical patent/CU20190056A7/es
Publication of CU24573B1 publication Critical patent/CU24573B1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)

Abstract

<p>La presente invención se refiere a 6 ácidos carboxílicos de benzimidazoles y 4-aza, 5-aza, 7-aza y 4,7-diaza-benzimidazoles como agonistas de GLP-1R, de fórmula general I:</p> <p>ESPACIO PARA LA FÓRMULA</p> <p>útiles en el tratamiento o prevención de enfermedades cardiometabólicas como diabetes, pre-diabetes, esteatohepatitis no alcohólica y enfermedad cardiovascular.</p>
CU2019000056A 2016-12-16 2017-12-01 Ácidos carboxílicos de benzimidazoles y 4-aza, 5-aza, 7-aza y 4,7-diaza-benzimidazoles como agonistas receptores de glp-1, útiles para tratar o prevenir enfermedades cardiometabólicas CU24573B1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662435533P 2016-12-16 2016-12-16
PCT/IB2017/057577 WO2018109607A1 (en) 2016-12-16 2017-12-01 Glp-1 receptor agonists and uses thereof

Publications (2)

Publication Number Publication Date
CU20190056A7 true CU20190056A7 (es) 2020-01-03
CU24573B1 CU24573B1 (es) 2022-01-13

Family

ID=60702906

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2019000056A CU24573B1 (es) 2016-12-16 2017-12-01 Ácidos carboxílicos de benzimidazoles y 4-aza, 5-aza, 7-aza y 4,7-diaza-benzimidazoles como agonistas receptores de glp-1, útiles para tratar o prevenir enfermedades cardiometabólicas

Country Status (40)

Country Link
US (7) US10208019B2 (es)
EP (1) EP3555064B9 (es)
JP (2) JP6637641B1 (es)
KR (2) KR102314286B1 (es)
CN (1) CN110325530B (es)
AR (1) AR110387A1 (es)
AU (1) AU2017374860B2 (es)
CA (1) CA2988721C (es)
CL (1) CL2019001651A1 (es)
CO (1) CO2019006046A2 (es)
CR (1) CR20190289A (es)
CU (1) CU24573B1 (es)
CY (1) CY1125716T1 (es)
DK (1) DK3555064T5 (es)
DO (1) DOP2019000166A (es)
EA (1) EA037318B1 (es)
EC (1) ECSP19041071A (es)
ES (1) ES2934789T3 (es)
FI (1) FI3555064T3 (es)
GE (2) GEAP202115110A (es)
HR (1) HRP20221437T1 (es)
HU (1) HUE060533T2 (es)
IL (1) IL267288B (es)
LT (1) LT3555064T (es)
MA (1) MA56480B1 (es)
MD (1) MD3555064T2 (es)
MX (1) MX387259B (es)
MY (1) MY195385A (es)
PE (1) PE20191501A1 (es)
PH (1) PH12019501360B1 (es)
PL (1) PL3555064T3 (es)
PT (1) PT3555064T (es)
RS (1) RS63849B9 (es)
RU (1) RU2740135C1 (es)
SI (1) SI3555064T1 (es)
TW (1) TWI713809B (es)
UA (1) UA122035C2 (es)
UY (1) UY37514A (es)
WO (1) WO2018109607A1 (es)
ZA (1) ZA201904616B (es)

Families Citing this family (180)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190090B1 (ar) 2016-10-24 2023-03-28 Astrazeneca Ab مشتقات 9،8،7،6-رابع هيدرو-3h-بيرازولو [4،3-f]أيزوكينولين مفيدة في علاج السرطان
JOP20190144A1 (ar) 2016-12-16 2019-06-16 Janssen Pharmaceutica Nv إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز
TWI831738B (zh) 2016-12-16 2024-02-11 美商瑞塔醫藥有限責任公司 用於抑制ＲＯＲγ及其他用途的嘧啶三環烯酮衍生物
CN110325530B (zh) 2016-12-16 2022-01-11 辉瑞大药厂 Glp-1受体激动剂及其用途
JP7291077B2 (ja) 2016-12-16 2023-06-14 ヤンセン ファーマシューティカ エヌ．ベー． Ｊａｋファミリーのキナーゼの低分子阻害物質
EP3689873B1 (en) 2017-01-30 2022-09-14 Astrazeneca AB Estrogen receptor modulators
EP3710831A4 (en) * 2017-11-15 2022-01-12 Beth Israel Deaconess Medical Center, Inc. MARKERS FOR THE DIAGNOSIS AND TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS (NASH) AND ADVANCED FIBROSIS OF THE HEPATER
EP3810610A1 (en) 2018-05-18 2021-04-28 Incyte Corporation Fused pyrimidine derivatives as a2a / a2b inhibitors
US10934279B2 (en) * 2018-06-13 2021-03-02 Pfizer Inc. GLP-1 receptor agonists and uses thereof
TW202016110A (zh) 2018-06-15 2020-05-01 比利時商健生藥品公司 Ｊａｋ激酶家族之小分子抑制劑
SG11202011704XA (en) * 2018-06-15 2020-12-30 Pfizer Glp-1 receptor agonists and uses thereof
CN112654610B (zh) 2018-06-15 2024-12-24 里亚塔医药公司 用于抑制IL-17和RORγ的吡唑和咪唑化合物
EP3810141A1 (en) 2018-06-20 2021-04-28 Reata Pharmaceuticals, Inc. Cysteine-dependent inverse agonists of nuclear receptors ror-gamma/ror-gamma-t and methods of treating diseases or disorders therewith
AU2019297361B2 (en) 2018-07-05 2024-06-27 Incyte Corporation Fused pyrazine derivatives as A2A / A2B inhibitors
BR112021003039A2 (pt) 2018-08-31 2021-05-18 Pfizer Inc. combinações para o tratamento de nash/nafld e doenças relacionadas
CU20210042A7 (es) 2018-11-22 2022-01-13 Qilu Regor Therapeutics Inc Compuestos agonistas de glp-1r y composiciones farmacéuticas que lo contienen
CN111320609A (zh) 2018-12-13 2020-06-23 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
BR112021020335A2 (pt) 2019-04-12 2021-12-14 Qilu Regor Therapeutics Inc Agonistas glp-1r e usos dos mesmos
CN114041057A (zh) 2019-04-29 2022-02-11 康福治疗有限公司 嵌合蛋白和筛选与gpcr结合的化合物和配体的方法
US12611401B2 (en) 2019-05-20 2026-04-28 Pfizer Inc. Combinations comprising benzodioxol as GLP-1R agonists for use in the treatment of NASH/NAFLD and related diseases
TWI751585B (zh) 2019-06-28 2022-01-01 美商美國禮來大藥廠 類升糖素肽1受體促效劑
CA3144848C (en) 2019-06-28 2023-11-21 Pfizer Inc. 5-(thiophen-2-yl)-1h-tetrazole derivatives as bckdk inhibitors useful for treating various diseases
TW202115086A (zh) 2019-06-28 2021-04-16 美商輝瑞大藥廠 Bckdk抑制劑
WO2021018023A1 (zh) * 2019-08-01 2021-02-04 济南泰达领创医药技术有限公司 小分子glp-1受体调节剂
PH12022550605A1 (en) 2019-09-13 2023-09-25 Nimbus Saturn Inc Hpk1 antagonists and uses thereof
TWI771766B (zh) 2019-10-04 2022-07-21 美商輝瑞股份有限公司 二醯基甘油醯基轉移酶２ 抑制劑
PE20221040A1 (es) * 2019-10-25 2022-06-17 Gilead Sciences Inc Compuestos moduladores de glp-1r
MA57692B1 (fr) * 2019-11-15 2025-04-30 Ildong Pharmaceutical Co., Ltd. Agoniste du récepteur glp-1 et son utilisation
KR20210059584A (ko) * 2019-11-15 2021-05-25 일동제약(주) Glp-1 수용체 작용제 및 이의 용도
EP4069686B1 (en) 2019-12-02 2025-01-22 Hyundai Pharm Co., Ltd. Glp-1 receptor agonist
WO2021116874A1 (en) * 2019-12-10 2021-06-17 Pfizer Inc. Solid forms of 2-((4-((s)-2-(5-chloropyridin-2-yl)-2-methylbenzo[d] [1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-benzo[d] imidazole-6-carboxylic acid, 1,3-dihydroxy-2-(hydroxymethyl)propan-2-amine salt
PL4073051T3 (pl) * 2019-12-10 2024-05-20 Eli Lilly And Company Sposób i związek pośredni do wytwarzania oksetan-2-ylometanoaminy
CA3168543A1 (en) 2020-01-29 2021-08-05 Gilead Sciences, Inc. Glp-1r modulating compounds
PE20231066A1 (es) 2020-02-07 2023-07-17 Gasherbrum Bio Inc Agonistas heterociclicos de glp-1
JP7836762B2 (ja) * 2020-02-13 2026-03-27 ガシャーブラム・バイオ・インコーポレイテッド ヘテロ環ｇｌｐ－１アゴニスト
JP2021134211A (ja) 2020-02-24 2021-09-13 ファイザー・インク Ｎａｆｌｄ／ｎａｓｈおよび関連疾患の処置のための組合せ
JP2022058085A (ja) 2020-02-24 2022-04-11 ファイザー・インク ジアシルグリセロールアシルトランスフェラーゼ２阻害剤とアセチル－ＣｏＡカルボキシラーゼ阻害剤との組合せ
KR102563111B1 (ko) * 2020-03-18 2023-08-04 주식회사 엘지화학 Glp-1 수용체 효능제, 이를 포함하는 약학적 조성물 및 이의 제조방법
MX2022011349A (es) * 2020-03-18 2022-11-10 Lg Chemical Ltd Agonista del receptor de glp-1, composición farmacéutica que comprende el mismo, y método para preparar el mismo.
IL296694A (en) * 2020-03-27 2022-11-01 Pfizer Treatment of type 2 diabetes, obesity or excess weight using 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[( 2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid or its pharmaceutical salts
CN113493447B (zh) * 2020-04-03 2024-06-11 轩竹(北京)医药科技有限公司 Glp-1受体激动剂
TW202144340A (zh) * 2020-04-03 2021-12-01 大陸商江蘇恆瑞醫藥股份有限公司 稠合咪唑類衍生物、其製備方法及其在醫藥上的應用
MX2022013258A (es) 2020-04-24 2022-11-14 Astrazeneca Ab Formulaciones farmaceuticas.
JP7712955B2 (ja) 2020-04-24 2025-07-24 アストラゼネカ・アクチエボラーグ 癌の治療のための投薬レジメン
EP4143183B1 (en) 2020-04-29 2025-10-22 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
PL4157832T3 (pl) * 2020-05-27 2024-12-16 Qilu Regor Therapeutics Inc. Sól i postacie krystaliczne agonistów GLP-1R oraz ich zastosowania
EP4155313B1 (en) * 2020-06-04 2025-08-27 Hangzhou Sciwind Biosciences Co., Ltd. Five-membered heteroaromatic imidazole compound and use thereof
PE20231215A1 (es) 2020-06-09 2023-08-17 Pfizer Compuestos espiro como antagonistas del receptor de melanocortina 4 y usos de los mismos
EP4166142A4 (en) * 2020-06-10 2024-06-26 Medshine Discovery Inc. Methyl-substituted benzobisoxazole compound and use thereof
CN113773310B (zh) * 2020-06-10 2023-12-22 重庆康丁医药技术有限公司 一种具有心血管益处的glp-1小分子
CN113816948B (zh) * 2020-06-19 2023-08-11 江苏恒瑞医药股份有限公司 稠合咪唑类衍生物、其制备方法及其在医药上的应用
CN115916772B (zh) * 2020-06-19 2025-01-14 江苏恒瑞医药股份有限公司 6-氧代-3,6-二氢吡啶类衍生物、其制备方法及其在医药上的应用
WO2021259309A1 (zh) * 2020-06-24 2021-12-30 广州市恒诺康医药科技有限公司 Glp-1受体激动剂及其药物组合物和用途
WO2022028572A1 (en) 2020-08-06 2022-02-10 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
TW202214622A (zh) 2020-08-06 2022-04-16 大陸商上海齊魯銳格醫藥研發有限公司 Ｇｌｐ－１ｒ促效劑及其用途
KR20230074486A (ko) * 2020-08-21 2023-05-30 테른스 파마슈티칼스, 인크. Glp-1r 효능제로서의 화합물
CN116406360A (zh) * 2020-08-28 2023-07-07 加舒布鲁姆生物公司 杂环glp-1激动剂
CN119930605A (zh) 2020-09-01 2025-05-06 江苏恒瑞医药股份有限公司 稠合咪唑类衍生物、其制备方法及其在医药上的应用
CA3192236A1 (en) 2020-09-10 2022-03-17 Tony Lahoutte Antibody fragment against fap
JP7858636B2 (ja) 2020-09-10 2026-05-14 ガシャーブラム・バイオ・インコーポレイテッド ヘテロ環ｇｌｐ－１アゴニスト
WO2022068772A1 (zh) * 2020-09-29 2022-04-07 深圳信立泰药业股份有限公司 一种苯并咪唑类衍生物及其制备方法和医药用途
CN116348464A (zh) * 2020-10-12 2023-06-27 杭州中美华东制药有限公司 苯并咪唑酮类glp-1受体激动剂及其用途
CN116547279A (zh) * 2020-10-13 2023-08-04 加舒布鲁姆生物公司 杂环glp-1激动剂
CN116547278A (zh) * 2020-10-13 2023-08-04 加舒布鲁姆生物公司 杂环glp-1激动剂
WO2022078352A1 (en) * 2020-10-14 2022-04-21 Qilu Regor Therapeutics Inc. Crystal forms of glp-1r agonists and uses thereof
CN114478497B (zh) * 2020-11-12 2023-10-20 杭州中美华东制药有限公司 芳基烷基酸类glp-1受体激动剂及其用途
WO2022109182A1 (en) * 2020-11-20 2022-05-27 Gilead Sciences, Inc. Polyheterocyclic glp-1 r modulating compounds
CA3200245A1 (en) * 2020-11-27 2022-06-02 Junjun Wu Benzimidazole derivative and preparation method therefor and medical use thereof
CN114591308B (zh) 2020-12-03 2024-03-08 苏州闻泰医药科技有限公司 一类glp-1r受体激动剂化合物及其用途
US12065434B2 (en) * 2020-12-15 2024-08-20 Pfizer Inc. Metabolites of GLP1R agonists
US20220193063A1 (en) * 2020-12-15 2022-06-23 Pfizer Inc. Metabolites of glp1r agonists
AU2021405918A1 (en) * 2020-12-25 2023-07-20 Xizang Haisco Pharmaceutical Co., Ltd. Five-membered ring derivative and medical use thereof
CN114805336B (zh) * 2021-01-20 2026-04-14 江苏恒瑞医药股份有限公司 稠合咪唑类化合物、其制备方法及其在医药上的应用
CN117043154A (zh) * 2021-01-28 2023-11-10 卡莫特医疗有限公司 Gpcr受体激动剂、包含其的药物组合物以及它们的使用方法
MX2023008854A (es) * 2021-01-28 2023-10-17 Carmot Therapeutics Inc Agonistas del receptor acoplado a proteinas g (gpcr), composiciones farmaceuticas que los comprenden y metodos para su uso.
WO2022174253A1 (en) 2021-02-12 2022-08-18 Nimbus Saturn, Inc. Hpk1 antagonists and uses thereof
WO2022184849A1 (en) 2021-03-04 2022-09-09 Les Laboratoires Servier Glp-1r agonists, uses and pharmaceutical compositions thereof
CN117295737A (zh) 2021-03-05 2023-12-26 林伯士萨顿公司 Hpk1拮抗剂和其用途
WO2022192430A1 (en) * 2021-03-11 2022-09-15 Gilead Sciences, Inc. Glp-1r modulating compounds
EP4304711A1 (en) 2021-03-11 2024-01-17 Gilead Sciences, Inc. Glp-1r modulating compounds
AU2022233254A1 (en) 2021-03-11 2023-10-26 Janssen Pharmaceutica Nv Lorpucitinib for use in the treatment of jak mediated disorders
CN116940561A (zh) 2021-03-22 2023-10-24 杭州中美华东制药有限公司 噻吩类glp-1受体激动剂及其用途
JP7772778B2 (ja) * 2021-03-24 2025-11-18 塩野義製薬株式会社 縮合環を有するｇｌｐ－１受容体作動薬を含有する医薬組成物
WO2022213062A1 (en) 2021-03-29 2022-10-06 Nimbus Saturn, Inc. Hpk1 antagonists and uses thereof
PL4271672T3 (pl) 2021-04-21 2026-04-20 Gilead Sciences, Inc. Karboksybenzimidazolowe związki modulujące glp-1r
EP4334304A1 (en) * 2021-05-03 2024-03-13 Carmot Therapeutics, Inc. Benzimidazoyl glp-1 receptor agonists, pharmaceutical compositions comprising the same, and methods for their use
TWI843104B (zh) * 2021-05-20 2024-05-21 美商美國禮來大藥廠 類升糖素肽1受體促效劑
MX2023014985A (es) * 2021-06-24 2024-02-14 Hangzhou Zhongmeihuadong Pharmaceutical Co Ltd Agonista del receptor de glp-1 y composicion y uso del mismo.
JP2024525900A (ja) * 2021-07-21 2024-07-12 ヘパジーン セラピューティクス（エイチケー）リミティド グルカゴン様ペプチド－１受容体モジュレーター及びその使用
CN113480534B (zh) * 2021-07-23 2022-05-13 广州必贝特医药股份有限公司 苯并咪唑或氮杂苯并咪唑-6-羧酸类化合物及其应用
WO2023011395A1 (zh) * 2021-08-02 2023-02-09 深圳信立泰药业股份有限公司 Glp-1r激动剂化合物的盐及其制备方法和医药用途
US20240360109A1 (en) * 2021-08-04 2024-10-31 Shanghai Hansoh Biomedical Co., Ltd. Cycloalkene derivative regulator, preparation method therefor, and application thereof
WO2023026180A1 (en) 2021-08-26 2023-03-02 Pfizer Inc. Amorphous form of (s)-2-(5-((3-ethoxypyridin-2-yl)oxy)pyridin-3-yl)-n-(tetrahydrofuran-3- yl)pyrimidine-5-carboxamide
WO2023029380A1 (zh) 2021-08-30 2023-03-09 杭州德睿智药科技有限公司 作为glp1r激动剂的新型芳醚取代杂环类化合物
CN117940422A (zh) * 2021-08-31 2024-04-26 辉瑞大药厂 2-[(4-{6-[(4-氰基-2-氟芐基)氧基]吡啶-2-基}哌啶-1-基)甲基]-1-[(2s)-氧杂环丁烷-2-基甲基]-1h-苯并咪唑-6-羧酸，1,3-二羟基-2-(羟甲基)丙-2-胺盐的固体形式
CN113548982B (zh) * 2021-09-03 2022-05-06 上海三牧化工技术有限公司 一种4-氰基-2-氟苄醇的制备方法
AU2022344074A1 (en) 2021-09-08 2024-02-29 Shionogi & Co., Ltd. Medicine for prevention and treatment of diseases linked to anti-obesity activity
FI4408840T3 (fi) * 2021-09-27 2025-11-04 Terns Pharmaceuticals Inc Bentsimidatsolikarboksyylihappoja glp-1r-agonisteina
WO2023057414A1 (en) 2021-10-05 2023-04-13 Astrazeneca Ab Certain octahydrofuro[3,4- b]pyrazines as glp-1 receptor modulators
WO2023057429A1 (en) 2021-10-05 2023-04-13 Astrazeneca Ab Certain 2,5-diazabicyclo[4.2.0]octanes and octahydrofuro[3,4- b]pyrazines as glp-1 receptor modulators
EP4412707A1 (en) 2021-10-05 2024-08-14 Astrazeneca AB Certain 2,5-diazabicyclo[4.2.0]octanes as glp-1 receptor modulators
TWI843243B (zh) * 2021-10-22 2024-05-21 大陸商盛世泰科生物醫藥技術（蘇州）股份有限公司 作為glp-1受體激動劑的化合物、包含其的藥物組成物及其用途
IL312364A (en) 2021-10-25 2024-06-01 Luehr Gary W Compounds as GLP-1R agonists
AU2022403203B2 (en) 2021-12-01 2025-09-25 Pfizer Inc. 3-phenyl-1-benzothiophene-2-carboxylic acid derivatives as branched-chain alpha keto acid dehydrogenase kinase inhibitors for the treatment of diabetes, kidney diseases, nash and heart failure
EP4441047A4 (en) * 2021-12-03 2025-03-19 Hangzhou Sciwind Biosciences Co., Ltd. CRYSTALLINE FORMS OF THIENOIMIDAZOLE COMPOUND AND PROCESS FOR THEIR PREPARATION
CA3241470A1 (en) 2021-12-06 2023-06-15 Pfizer Inc. Melanocortin 4 receptor antagonists and uses thereof
JPWO2023106310A1 (es) * 2021-12-07 2023-06-15
US20250042882A1 (en) 2021-12-16 2025-02-06 Astrazeneca Ab Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators
US20250066338A1 (en) 2021-12-16 2025-02-27 Astrazeneca Ab Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators
CN118434745A (zh) * 2021-12-29 2024-08-02 西藏海思科制药有限公司 一种glp-1激动剂的盐及其晶型和在医药上的应用
WO2023130878A1 (zh) * 2022-01-10 2023-07-13 海思科医药集团股份有限公司 一种glp-1激动剂盐及其晶型及在医药上的应用
JP2025506474A (ja) * 2022-02-09 2025-03-11 ガシャーブラム・バイオ・インコーポレイテッド ヘテロ環ｇｌｐ－１アゴニスト
WO2023151574A1 (en) * 2022-02-09 2023-08-17 Gasherbrum Bio Inc. Heterocyclic glp-1 agonists
US12410163B2 (en) 2022-02-23 2025-09-09 Terns Pharmaceuticals, Inc. Compounds as GLP-IR agonists
CA3245508A1 (en) * 2022-03-08 2025-01-22 Guangzhou Unirise Pharmaceutical Co., Ltd. BENZO BICYCLIC COMPOUND, ITS PREPARATION PROCESS AND ITS APPLICATION
JP2025509281A (ja) * 2022-03-09 2025-04-11 ガシャーブラム・バイオ・インコーポレイテッド ヘテロ環式ｇｌｐ－１アゴニスト
EP4496797A1 (en) 2022-03-21 2025-01-29 Gasherbrum Bio, Inc. 5,8-dihydro-1,7-naphthyridine derivatives as glp-1 agonists for the treatment of diabetes
WO2023182869A1 (en) * 2022-03-25 2023-09-28 Ildong Pharmaceutical Co., Ltd. Novel salt of glp-1 receptor agonist compound, preparation method thereof and pharmaceutical composition comprising thereof
EP4508047A1 (en) 2022-04-14 2025-02-19 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
WO2023203135A1 (en) 2022-04-22 2023-10-26 Precirix N.V. Improved radiolabelled antibody
AU2023264245A1 (en) 2022-05-02 2024-12-19 Precirix N.V. Pre-targeting
CN120289354A (zh) * 2022-07-18 2025-07-11 厦门市博瑞来医药科技有限公司 五元并六元化合物、其中间体、制备方法、组合物和应用
WO2024018395A1 (en) * 2022-07-22 2024-01-25 Pfizer Inc. Methods and intermediates for preparing 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid, 1,3-dihydroxy-2-(hydroxymethyl)propan-2-amine salt
CN115536638B (zh) * 2022-08-15 2023-10-13 上海交通大学 一种三氮唑类化合物及其应用
WO2024051700A1 (zh) * 2022-09-05 2024-03-14 德睿智药(苏州)新药研发有限公司 作为glp1r激动剂的新型芳基氘代苄醚取代杂环类化合物
MX2025002598A (es) * 2022-09-06 2025-05-02 Mindrank Therapeutics Suzhou New Drug Res And Development Co Ltd Polimorfo de compuesto agonista de glp-1r, método de preparación para el mismo, y uso de este
EP4592285A1 (en) 2022-09-22 2025-07-30 Shionogi & Co., Ltd. Fused ring compound having glp-1 receptor agonist effect
IL319486A (en) 2022-10-07 2025-05-01 Pfizer HSD17B13 Inhibitors and/or Retarders
CN120129681A (zh) 2022-10-18 2025-06-10 辉瑞大药厂 含Patatin样磷脂酶结构域的蛋白3（PNPLA3）调节剂
KR20250105662A (ko) * 2022-11-11 2025-07-08 일라이 릴리 앤드 캄파니 글루카곤-유사 펩티드 1 수용체 효능제
EP4619098A1 (en) 2022-11-16 2025-09-24 Eli Lilly and Company Glucagon-like peptide 1 receptor agonists
AU2023394509A1 (en) * 2022-12-13 2025-07-10 Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. Salt-type glp-1 receptor agonist, crystal form thereof, preparation method therefor, pharmaceutical composition thereof, and use thereof
JP2025541231A (ja) 2022-12-16 2025-12-18 ファイザー・インク ３－フルオロ－４－ヒドロキシベンズアミド含有阻害剤および／または分解剤ならびにそれらの使用
WO2024149080A1 (zh) 2023-01-13 2024-07-18 中国科学院上海药物研究所 用作glp-1受体激动剂的4-烷氧基苯并咪唑-6-羧酸衍生物
AU2024213693A1 (en) * 2023-02-02 2025-09-11 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Salt and crystal form of cycloalkene compound, and preparation method therefor and use thereof
CN118496200A (zh) * 2023-02-14 2024-08-16 成都康弘药业集团股份有限公司 吲唑啉酮类化合物及其制备方法和用途
IL322686A (en) 2023-02-16 2025-10-01 Gasherbrum Bio Inc Heterocyclic glp-1 agonists
TW202504595A (zh) * 2023-03-29 2025-02-01 美商拓臻製藥公司 Ｇｌｐ—１ｒ促效劑之多晶型及鹽
WO2024211898A1 (en) 2023-04-07 2024-10-10 Terns Pharmaceuticals, Inc. Combination comprising a thrbeta agonist anda glp-1r agonist for use in treating a liver disorder or a cardiometabolic disease
WO2024212742A1 (zh) * 2023-04-10 2024-10-17 上海研健新药研发有限公司 一种glp-1r激动剂，其制备方法和应用
EP4695226A1 (en) 2023-04-14 2026-02-18 Pfizer Inc. Glucose-dependent insulinotropic polypeptide receptor antagonists and uses thereof
CN118812522A (zh) * 2023-04-21 2024-10-22 苏州闻泰医药科技有限公司 一种glp-1r受体激动剂化合物盐、其晶型、其制备方法和应用
EP4744660A1 (en) 2023-07-12 2026-05-20 Ascletis Pharma China Co Ltd GLP-1R AGONIST PREPARATION AND ITS PREPARATION PROCESS
EP4743174A1 (en) 2023-07-13 2026-05-20 Aconcagua Bio Inc CALCITONIN AND/OR AMYLIN RECEPTOR ACTIVITY MODULATORS
AR133241A1 (es) 2023-07-13 2025-09-10 Aconcagua Bio Inc Compuestos, composiciones y métodos
CN119330949A (zh) 2023-07-21 2025-01-21 石药集团中奇制药技术（石家庄）有限公司 一类多环化合物及其用途
CN116675680B (zh) * 2023-08-02 2023-10-20 药康众拓(北京)医药科技有限公司 一种氘代化合物及其制备方法、药物和应用
AU2024340407A1 (en) 2023-09-14 2026-04-23 Ascletis Pharma (China) Co., Limited Glp-1r agonist and therapeutic method thereof
CN121889388A (zh) * 2023-09-21 2026-04-17 尹诺卫医药有限公司 制备取代的稠合咪唑衍生物的方法
WO2025069009A1 (en) 2023-09-29 2025-04-03 Graviton Bioscience Bv Rock2 inhibitors in the treatment of obesity
WO2025083727A1 (en) * 2023-10-20 2025-04-24 Dr. Reddy's Laboratories Limited Amorpous solid dispersons of danuglipron free acid and process thereof
WO2025099561A1 (en) 2023-11-07 2025-05-15 Pfizer Inc. Oral controlled-release matrix formulations of 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid or a pharmaceutically salt thereof
US20250163168A1 (en) 2023-11-17 2025-05-22 Pfizer Inc. Novel antibodies and antibody conjugates for the treatment of metabolic disorders
WO2025109387A1 (en) 2023-11-24 2025-05-30 Ascletis Pharma (China) Co., Limited Glp-1r agonist and therapeutic method thereof
TW202542163A (zh) * 2023-12-27 2025-11-01 香港商英矽智能科技知識產權有限公司 作為ｇｌｐ－１ｒ激動劑的新型化合物及其用途
TW202543613A (zh) * 2023-12-27 2025-11-16 香港商英矽智能科技知識產權有限公司 作為ｇｌｐ－１ｒ激動劑的新型化合物及其用途
WO2025158275A1 (en) * 2024-01-24 2025-07-31 Pfizer Inc. Combination therapy using glucose-dependent insulinotropic polypeptide receptor antagonist compounds and glp-1 receptor agonist compounds
TW202539633A (zh) 2024-02-01 2025-10-16 美商輝瑞股份有限公司 葡萄糖依賴性促胰島素多肽受體拮抗劑及其用途
WO2025171341A2 (en) 2024-02-08 2025-08-14 Aconcagua Bio, Inc. Compounds and compositions for treating conditions associated with calcitonin receptor and/or amylin receptor activity
WO2025171340A1 (en) 2024-02-08 2025-08-14 Aconcagua Bio, Inc. The treatment of calcitonin- and/or amylin-receptor associated conditions
KR20250125490A (ko) 2024-02-14 2025-08-22 주식회사 종근당 Glp-1 수용체 작용제 및 이의 용도
WO2025171806A1 (en) * 2024-02-18 2025-08-21 Rezubio Pharmaceuticals Co., Ltd Methods for weight management and mitigation of vesceral malaise
WO2025189141A1 (en) 2024-03-08 2025-09-12 Annapurna Bio, Inc. Methods for treating obesity and increasing weight loss
TW202541834A (zh) * 2024-04-16 2025-11-01 南韓商韓美藥品股份有限公司 吸入用組成物
TW202600540A (zh) 2024-04-22 2026-01-01 美商輝瑞大藥廠 葡萄糖依賴性促胰島素多肽受體拮抗劑及其用途
WO2025252098A1 (zh) * 2024-06-05 2025-12-11 杭州中美华东制药有限公司 Glp-1受体激动剂的口服药物组合物及其制备方法
WO2026013531A1 (en) 2024-07-10 2026-01-15 Pfizer Inc. Spiro[2.5]octane compounds
WO2026033382A1 (en) 2024-08-07 2026-02-12 Pfizer Inc. Heterocyclic glp-1r modulators
WO2026042018A1 (en) 2024-08-21 2026-02-26 Pfizer Inc. 4-{4-[(1-{[4-(propan-2-yl)phenyl]carbamoyl)-d-prolyl)amino]cyclohexyl}benzoic acid derivatives as gipr antagonists for the treatment of diabetes
WO2026051998A1 (en) 2024-09-04 2026-03-12 Aconcagua Bio, Inc. Compounds, compositions, and methods
WO2026078617A1 (en) 2024-10-11 2026-04-16 Pfizer Inc. Glucose-dependent insulinotropic polypeptide receptor antagonists and uses thereof
WO2026078673A1 (en) 2024-10-13 2026-04-16 Pfizer Inc. Glucose-dependent insulinotropic polypeptide receptor antagonists and uses thereof
WO2026078674A1 (en) 2024-10-13 2026-04-16 Pfizer Inc. Heterocyclic derivatives as glucose-dependent insulinotropic polypeptide receptor antagonists and uses thereof
WO2026078672A1 (en) 2024-10-13 2026-04-16 Pfizer Inc. Glucose-dependent insulinotropic polypeptide receptor antagonists and uses thereof
WO2026078671A1 (en) 2024-10-13 2026-04-16 Pfizer Inc. Heterocyclic compounds as glucose-dependent insulinotropic polypeptide receptor antagonists
WO2026078670A1 (en) 2024-10-13 2026-04-16 Pfizer Inc. Heterocyclic derivatives as glucose-dependent insulinotropic polypeptide receptor antagonists
WO2026088071A1 (en) 2024-10-23 2026-04-30 Pfizer Inc. Substituted fused heteroaryl lactam compounds
WO2026086915A1 (en) * 2024-10-25 2026-04-30 Insilico Medicine Ip Limited Glucose-dependent insulinotropic polypeptide receptor (gipr) antagonists and methods of uses thereof
WO2026096926A1 (en) 2024-11-01 2026-05-07 Aconcagua Bio, Inc. Compounds, compositions, and methods

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
GB9305623D0 (en) 1993-03-18 1993-05-05 Merck Sharp & Dohme Therapeutic agents
JPH08508030A (ja) 1993-03-18 1996-08-27 メルク シヤープ エンド ドーム リミテツド ベンゾイミダゾール誘導体
US20020169166A1 (en) * 2001-03-09 2002-11-14 Cowart Marlon D. Benzimidazoles that are useful in treating sexual dysfunction
US6960589B2 (en) * 2001-03-09 2005-11-01 Abbott Laboratories Benzimidazoles that are useful in treating sexual dysfunction
SE0100903D0 (sv) * 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
US20040127504A1 (en) * 2002-09-06 2004-07-01 Cowart Marlon D. Benzimidazoles that are useful in treating sexual dysfunction
AU2006288153A1 (en) 2005-09-07 2007-03-15 Msd K.K. Bicyclic aromatic substituted pyridone derivative
WO2008012623A1 (en) 2006-07-25 2008-01-31 Pfizer Products Inc. Benzimidazolyl compounds as potentiators of mglur2 subtype of glutamate receptor
WO2010022055A2 (en) 2008-08-20 2010-02-25 Amgen Inc. Inhibitors of voltage-gated sodium channels
SG174125A1 (en) 2009-04-02 2011-10-28 Merck Serono Sa Dihydroorotate dehydrogenase inhibitors
NZ603876A (en) * 2010-05-13 2015-02-27 Amgen Inc Nitrogen heterocyclic compounds useful as pde10 inhibitors
MX348131B (es) 2011-02-25 2017-05-26 Merck Sharp & Dohme Novedosos derivados de azabencimidazol ciclico utiles como agentes antidiabeticos.
CN110325530B (zh) 2016-12-16 2022-01-11 辉瑞大药厂 Glp-1受体激动剂及其用途

Also Published As

Publication number Publication date
US20200255406A1 (en) 2020-08-13
CA2988721C (en) 2023-09-05
IL267288B (en) 2021-06-30
JP6982054B2 (ja) 2021-12-17
LT3555064T (lt) 2023-01-10
RU2740135C1 (ru) 2021-01-11
US10851081B2 (en) 2020-12-01
GEAP202115110A (en) 2021-02-25
ZA201904616B (en) 2021-05-26
SI3555064T1 (sl) 2023-02-28
TW201835066A (zh) 2018-10-01
PE20191501A1 (es) 2019-10-22
JP2020511411A (ja) 2020-04-16
WO2018109607A1 (en) 2018-06-21
GEP20217265B (en) 2021-06-25
EP3555064B1 (en) 2022-11-23
RS63849B1 (sr) 2023-01-31
ES2934789T9 (es) 2023-04-26
IL267288A (en) 2019-08-29
US10669259B2 (en) 2020-06-02
US20250257052A1 (en) 2025-08-14
US20180170908A1 (en) 2018-06-21
EA201991193A1 (ru) 2020-01-15
AU2017374860B2 (en) 2021-09-02
KR102314286B1 (ko) 2021-10-21
BR112019012211A2 (pt) 2019-11-12
AU2017374860A1 (en) 2019-06-20
JP6637641B1 (ja) 2020-01-29
US20210047298A1 (en) 2021-02-18
CN110325530B (zh) 2022-01-11
CO2019006046A2 (es) 2019-06-19
ES2934789T3 (es) 2023-02-27
MA56480B1 (fr) 2022-12-30
MX387259B (es) 2025-03-18
US12319669B2 (en) 2025-06-03
HUE060533T2 (hu) 2023-03-28
MY195385A (en) 2023-01-18
PL3555064T3 (pl) 2023-03-06
CR20190289A (es) 2019-08-21
ECSP19041071A (es) 2019-06-30
PH12019501360A1 (en) 2020-02-10
DK3555064T5 (da) 2023-05-01
CU24573B1 (es) 2022-01-13
UA122035C2 (uk) 2020-08-25
CY1125716T1 (el) 2024-02-16
EP3555064A1 (en) 2019-10-23
DK3555064T3 (da) 2022-12-12
FI3555064T3 (fi) 2023-01-31
KR102466418B1 (ko) 2022-11-14
UY37514A (es) 2018-07-31
KR20190094433A (ko) 2019-08-13
RS63849B9 (sr) 2023-06-30
CN110325530A (zh) 2019-10-11
CA2988721A1 (en) 2018-06-16
US10208019B2 (en) 2019-02-19
AR110387A1 (es) 2019-03-27
PH12019501360B1 (en) 2024-02-21
CL2019001651A1 (es) 2019-10-04
MX2019007077A (es) 2019-08-01
JP2020063287A (ja) 2020-04-23
MA56480A (fr) 2022-04-27
US20240034725A1 (en) 2024-02-01
NZ754428A (en) 2024-05-31
TWI713809B (zh) 2020-12-21
PT3555064T (pt) 2023-01-20
DOP2019000166A (es) 2019-07-31
US20230124938A1 (en) 2023-04-20
US20190119255A1 (en) 2019-04-25
HRP20221437T1 (hr) 2023-02-03
US11512070B2 (en) 2022-11-29
US11802121B2 (en) 2023-10-31
EP3555064B9 (en) 2023-03-01
EA037318B1 (ru) 2021-03-11
MD3555064T2 (ro) 2023-08-31
KR20210127782A (ko) 2021-10-22

Similar Documents

Publication Publication Date Title
CU24573B1 (es) Ácidos carboxílicos de benzimidazoles y 4-aza, 5-aza, 7-aza y 4,7-diaza-benzimidazoles como agonistas receptores de glp-1, útiles para tratar o prevenir enfermedades cardiometabólicas
CU20200099A7 (es) Compuestos derivados sustituidos de ácidos 6-carboxílicos de bencimidazoles y 4-aza-, 5-aza y 7-aza- benzimidazoles como agonistas glpr-1 útiles para el tratamiento o prevención de enfermedades cardiometabólicas y asociadas
PE20181295A1 (es) Metodos y composiciones para tratar afecciones asociadas a una respuesta inflamatoria anomala
CO2018000078A2 (es) Compuestos co-agonistas del glucagón y péptido-1 similar al glugacón (glp-1)
ECSP11011541A (es) Antagonistas de la trayectoria hedgehog de ftalazina disustituida
PA8740901A1 (es) Compuestos organicos
BR112013032717A2 (pt) coagonistas do receptor de glucagon/glp-1
MX388904B (es) Agonistas de glucagon/peptido similar al glucagon de tipo 1 (glp-1) para el tratamiento de la obesidad.
DOP2013000267A (es) Hidroximetil pirrolidinas como agonistas del receptor adrenérgico beta 3
CR20120303A (es) Tratamientos para trastornos gastrointestinales
PE20190117A1 (es) Compuestos de mic-1 y usos de estos
PE20130815A1 (es) Una composicion de combinacion farmaceutica y metodos para tratar la diabetes y los trastornos metabolicos
CO6382123A2 (es) Antagonistas de la via hedgehog de ftalazina disustituida
AR100365A1 (es) Composición acuosa que comprende ibuprofeno y paracetamol en combinación, proceso para fabricarla y dispositivo inyector para administrarla
MX381944B (es) Lixisenatida para usarse en el tratamiento de diabetes mellitus de tipo 2 en pacientes pediàtricos.
PH12017501122A1 (en) Substituted pyridyl-cycloalkyl-carboxylic acids, compositions containing them and medical uses thereof
PH12015500890A1 (en) Vaccine for preventing porcine edema disease
PE20160847A1 (es) Nuevo compuesto para el tratamiento de hipoglicemia severa
DOP2016000096A (es) Nuevo compuesto para el tratamiento de hipoglicemia severa
AR098616A1 (es) Péptido para el tratamiento de hipoglicemia severa
CL2017003143A1 (es) Composición multi-péptido.
CL2009000859A1 (es) Compuestos derivados de 4-{(4-carboxi-2-[(((6-(2-fenil-4-ciclopropil)-pirimidil)-carbonil)-amino]-butiril}-piperazin-1-carboxilo sustituido, antagonistas de receptores p2y12; composicion farmaceutica que los contiene y su uso para el tratamiento de afecciones vasculares oclusivas.
EA201791103A1 (ru) Терапевтический гомодимер и его применения
UA87652U (uk) Спосіб отримання сполуки з потенційними фізіологічними властивостями 1,1-діетилкарбокси-2-хлор-2-трифторметилетилен
UA87649U (uk) Спосіб отримання сполуки з потенційними фізіологічними властивостями 1-1-діетилкарбокси-2-метокси-2-трифторметилетилен